# Characterizing Declines in US Overdose Deaths Compared to Exponential Predictions

Joseph R. Friedman, MD, PhD, MPH[1*], Joseph J. Palamar, PhD[2], Daniel Ciccarone, MD[3], Tommi L. Gaines, DrPH[4], Annick Borquez, PhD[4], Chelsea L. Shover, PhD[5], Steffanie A. Strathdee, PhD[4]

[1]Department of Psychiatry, University of California, San Diego, San Diego, CA

[2]Department of Population Health, NYU Grossman School of Medicine, New York, NY

[3]Department of Family Community Medicine, University of California, San Francisco, San Francisco, CA

[4]Department of Medicine, University of California, San Diego, San Diego, San Diego, CA

[5]Department of Medicine, University of California Los Angeles, Los Angeles, CA

*Correspondence to:

Joseph Friedman, MD PhD, MPH, University of California, San Diego, 200 W Arbor Dr, San Diego, CA, 92103. jofriedman@health.ucsd.edu

**Word Count:** 2,997/3,000 words

## Key Points

### Question

To what extent are recent decreases in US overdose mortality deviating from prior exponential growth, and how have substance-specific, racial/ethnic, and geographic trends shifted?

### Findings

Decreases in overdose deaths between June 2023 and December 2024 represent the first significant large magnitude drop below the exponential growth curve, driven by falling illicit fentanyl mortality. However, deaths involving stimulants and xylazine continue to rise. The Western US shifted from the least-affected region to the most affected by overdose mortality. Racial gaps remain large but shrunk by a modest margin.

### Meaning

The course of the US overdose crisis is no longer consistent with an exponential growth curve, but novel substances and adulterants represent a potential driver of increased deaths in the future. Shifts occurring in 2024 were disproportionate by geography and race/ethnicity.

## Abstract

**Importance**

After decades of growth described nearly perfectly with an exponential curve, US overdose

mortality has begun to decrease.

**Objective**

To determine whether decreases in overdose mortality between 2023 and 2024 deviate from a

previously defined exponential growth curve, and assess how they differ by substance

involvement, geography, race/ethnicity, demographic, and other key dimensions.

**Design, Setting, and Participants**

Observational study examining overdose deaths in the US between January 1980-December

2024. Mortality trends were compared to an exponential growth curve, fit on data from 1980 to

2016.

**Exposures**

Year and month of occurrence of overdose death; substance involvement; census region and

division; state; county; race/ethnicity, age, and sex.

**Main Outcome and Measures**

Annual or monthly (annualized) overdose deaths per 100,000 population.

**Results**

After precipitously surpassing exponential growth predictions in 2020-2023, overdose deaths

fell sharply from approximately 32 per 100,000 in 2021-2023 to 23.7 in 2024, below the lower

bound of the exponential curve prediction (24.98) for the first time since 2001. Monthly data

show consistent decreases between June 2023 and December 2024. Decreases reflected

declining illicit fentanyl-involved deaths (with and without stimulants); however, deaths

involving stimulants without fentanyl, and those involving xylazine, continued to increase in

2024. Death rates in the Northeast, South and Midwest fell to 19.5, 19.4 and 17.3 per 100,000,

respectively, in December 2024, but remained elevated in the West at 27.2 per 100,000. Non-

Hispanic Black and African Americans had the largest decrease in death rates in 2023-2024

falling 29.3%, but remained elevated at 36.0 per 100,000, compared to the national average of

23.7 per 100,000. Non-Hispanic American Indian and Alaska Native individuals had the highest

overdose mortality rate in 2024, at 50.8 per 100,000.

**Conclusions and Relevance**

Recent decreases in overdose deaths are encouraging, unprecedented, and represent the first

significant, large-magnitude deviation below exponential growth. However, policymakers,

clinicians, and public health officials should be prepared for the possibility that a resurgence

could occur, especially if novel synthetic drugs change the risk environment of illicit drug use.

Stimulants and xylazine continue to represent increasingly important public health challenges.

Racial gaps remained large but shrunk by a modest margin.

**Introduction**

Overdose death rates in the US have begun decreasing, drawing considerable public attention.[1]

Earlier data described these trends at the national level,[2] with an overall downtrend beginning

mid-year 2023.[3] However, more updated and detailed information is needed to inform

prevention efforts, including a) how significantly these decreases in overdose mortality deviate

from previous exponential growth trends, and b) how they differ by substance involvement,

geography, race/ethnicity, and demographic categories.

Overdose deaths in the US have been characterized with a 'four wave' paradigm, wherein an

escalating overdose crisis was attributed to shifting drug profiles over time.[4–6] The first wave

was characterized by widespread access to prescription opioids—directly or indirectly through

the healthcare system—leading to a surge in deaths involving commonly prescribed opioids.[7] As

opioid deprescription limited access, in wave two, heroin filled the void left in the illicit opioid

market, and heroin-involved deaths predominated.[8] Wave three involved the market takeover

of illicitly-manufactured synthetic opioids, primarily fentanyls, whereby fentanyl-involved deaths

came to represent the largest share of overdose mortality.[8] As fentanyl induced shifts in the

illicit market and drug consumption behaviors, it ushered in the fourth wave, characterized by a

rise in polysubstance overdose deaths, especially involving the combination of fentanyl with

illicit stimulants such as cocaine and methamphetamine.[4,5] Deaths involving the combination of

fentanyl with the veterinary sedative xylazine also increased during this period.[9,10]

These four waves of the overdose crisis have seen epidemiological differences by geography and

race/ethnicity. Overdose death rates have historically been lower in the Western US, although

the region has started to 'catch up' as illicit fentanyl arrived to the West.[11] The third and fourth

waves of the overdose crisis have also driven sharp racial and ethnic inequalities in overdose,

with Black and African Americans, as well as American Indian and Alaska Natives

disproportionately affected.[12] One study found that mortality decreased among Non-Hispanic

White individuals, but as of 2023, were still increasing among the most affected racial/ethnic

minority groups, suggesting widening disparities despite overall gains at the population level.[3]

More recent evidence is needed to evaluate if racial/ethnic minority communities are now

experiencing similar decreases in overdose trends.

More insight is also needed to contextualize what recent decreases may mean for the long-term

course of the overdose crisis in the US.  As Jalal et al. noted in 2018, US overdose mortality

between 1980 and 2016 followed a nearly mathematically perfect exponential growth curve.[6]

Although overdose death rates have generally followed this pattern for the past four decades,

previous smaller-magnitude exceptions have been described. For instance, after growth

surpassed exponential predictions during 2016-2017—likely due, in part, to a transient spike in

carfentanil-related deaths—decreases occurred in 2018, representing a return to the

exponential growth curve.[13] It remains to be determined whether high magnitude increases in

overdose mortality occurring during the COVID-19 pandemic,[14] and more recent decreases,[3]

remain consistent with an overall exponential growth curve or if new patterns are emerging.

Here, we leverage recent records to describe overdose trends between January 1980-December

2024. We evaluate whether mortality rates remained consistent with an overall exponential

growth curve, and assess trends by substance-involvement, race/ethnicity, geography and

demographics.

**Methods**

Nationally representative drug overdose death data from the National Vital Statistics System

(NVSS) were obtained describing the 1980-2024 period. Drug overdose deaths were defined by

ICD-10 underlying cause of death codes X40–X44 (unintentional), X60–X64 (suicide), X85

(homicide), and Y10–Y14 (undetermined intent).[15] Recorded deaths from 2024 were provisional

and may slightly underestimate finalized records, whereas records from 2023 and prior were

finalized. Data on deaths between 1999 and 2024 were obtained for overdose-related deaths

overall and stratified by year, month, race/ethnicity, geography, and substance-involvement via

the Centers for Disease Control and Prevention (CDC) Wide-ranging ONline Data for

Epidemiologic Research (WONDER) platform.[15] As the CDC WONDER platform does not provide

records before 1999, mortality rates at the national level between 1980 and 1998 were

obtained from a separate publication using NVSS data.[16]

Substance involvement was characterized using ICD-10 multiple cause of death codes including

prescription opioids (T40.2), heroin (T40.1), synthetic opioids (primarily and herein referred to

as fentanyl) (T40.4),[5] cocaine (T40.5), psychostimulants with abuse potential (primarily and

herein referred to as methamphetamine) (T43.6),[17] and xylazine (T42.7 or T46.5).[9] Of note,

T40.4 and T43.6 represent umbrella codes for 'Other Synthetic Narcotics' and 'Psychostimulants

with Abuse Potential' respectively, which are widely used in epidemiological research to

represent illicit fentanyl and methamphetamine, respectively, as they mostly code for these

substances.[9,17,18] For simplicity, we use the terms 'fentanyl' and 'methamphetamine' throughout

the text. Nevertheless, a small number of other substances (such as nitazenes or U-compounds,

in the case of T40.4) are also represented by these codes.

To recreate the exponential curve defined by Jalal et al., we fit a bivariate linear regression

model with the outcome as the natural log of deaths per 100,000 population and the

explanatory variable of year of occurrence, using national overdose death data from 1980 to

2016.[6] The model was linearly extrapolated to make predictions for 2017-2024. Observed

trends between 1980 and 2024 were compared to model predictions, with 95% confidence

intervals, drawn from the fitted model assuming a normal distribution. All analyses were

conducted in R version 4.4.1.

**Results**

Figure 1 provides a simplified schema representing the four waves of the US overdose crisis.

Wave one reflects deaths due to prescription opioids (with fentanyl co-involvement omitted),

wave two is shown by deaths involving heroin (with fentanyl co-involvement omitted). Waves

three and four correspond to fentanyl-involved deaths without and with stimulant co-

involvement, respectively. Xylazine-involved deaths, and deaths involving stimulants without

fentanyl co-involvement are also shown as key drug mortality trends that are not decreasing.

During the COVID-19 pandemic in 2020, overdose mortality per 100,000 population rose sharply

above the exponential growth curve defined by Jalal et al (Figure 2A). Rates remained elevated

above the curve prediction, albeit relatively flat at about 32 deaths per 100,000 population,

between 2021 and 2023. In 2024, national overdose mortality fell precipitously to 23.7 per

100,000, dropping below the lower bound of the exponential curve prediction (which was 24.98

per 100,000) for the first time since 2001 (and for the first time ever to a large-magnitude

degree). Month-to-month trends highlight that mortality began to fall in June 2023 and

decreased steadily through December 2024 (Figure 3).

Overdose mortality has been characterized by a shifting profile of related drugs over time

(Figure 2B). The contributions of prescription opioids, heroin, and fentanyl without, and with

stimulants (roughly corresponding to waves 1-4 of the overdose crisis, respectively)[5] are

declining in the latest data. Mortality rates for overdose deaths involving prescription opioids

and heroin (with fentanyl co-involved deaths omitted) reached inflection points and began to

fall in 2016 and 2015, respectively, marking the decline of waves one and two of the crisis.

Overdose mortality rates involving illicit fentanyl without stimulant co-involvement began to fall

in 2022, marking the decline of wave three of the overdose crisis. Overdose death rates

involving fentanyl with stimulants declined for the first time in 2024, beginning the decline of

wave four. Deaths involving methamphetamine (without fentanyl co-involvement) and cocaine

(without fentanyl co-involvement) continued increasing between 2023 and 2024, consistent

with an overall trend of increasing stimulant-related deaths. Deaths involving xylazine also

represented an increasing proportion of fentanyl-involved deaths between 2023 and 2024,

rising from being co-involved in 8.3% of fentanyl-involved overdose deaths in 2023 to 12.6% of

fentanyl-involved deaths in 2024.

The overall decrease in overdose deaths in the US in 2023-2024 has been largely driven by

declines in deaths involving illicit fentanyl (Figure 4). Fentanyl-involved deaths without and with

stimulants dropped from 31,193 and 41,583 in 2023 respectively to 19,673 and 28,062

respectively in 2024. In contrast, the number of deaths involving stimulants, without fentanyl,

grew from 18,142 in 2023 to 18,907 in 2024, representing 17.3% of all overdose deaths in 2023,

and 23.8% of overdose deaths in 2024 (Figure 4).

Overdose mortality decreased differentially by region (Figure 3; Figure 5). In 2018, the

Northeast had the highest overdose death rates, followed by the South and Midwest, with the

West considerably lower (Figure 3). In 2024, overdose mortality in the West surpassed that of

other regions. Death rates in the Northeast, South and Midwest fell to 19.5, 19.4 and 17.3 per

100,000 respectively in December 2024, whereas in the West they remained more elevated, at

27.2 per 100,000 in December 2024. Between 2023 and 2024 death rates fell by 28.7% in the

Northeast, 28.2% in the Midwest, and 26.5% in the South, compared to 14.7% in the West.

Among Census divisions, the largest decreases between 2023 and 2024 were observed in East

North Central (which includes Illinois, Indiana, Michigan, Ohio, and Wisconsin) with a 30.5%

decline, and the South Atlantic (Delaware, Florida, Georgia, Maryland, North Carolina, South

Carolina, Virginia, West Virginia, and Washington, D.C.) with a decline of 29.2%. The smallest

decreases were observed in the Mountain Division (including Arizona, Colorado, Idaho,

Montana, Nevada, New Mexico, Utah, and Wyoming) with 9.7% and the Pacific (Alaska, Hawaii,

California, Oregon, and Washington) with 17.2%. Among states, the largest decreases during

this period were observed in West Virginia (40.4% decrease), Virginia (29.7% decrease) and

Delaware (32.7% decrease). Hawaii and South Dakota were the only states to register an

increase in overdose mortality between 2023 and 2024. (4.0% and 3.1% increases, respectively),

and Utah and Nevada experienced modest decreases (2.7% and 3.5% respectively; Figure 6). In

2024, the highest overall overdose death rates were in Washington, D.C. (46.4 per 100,000) and

West Virginia (46.4 per 100,000) whereas Nebraska (7.8 per 100,000), South Dakota (10.7 per

100,000), and Iowa (13.3 per 100,000) had the lowest rates.  Among the ten counties with the

largest numbers of deaths in 2024, Wayne County, Michigan (home to Detroit) and Cook County,

Illinois (home to Chicago) had the largest relative decreases (41.6% and 30.3%, respectively).

Clark County, Nevada (home to Las Vegas) saw a small increase in deaths (3.0%) and Maricopa

County, Arizona (home to Phoenix) experienced the smallest decrease of 3.6%.

Decreases in overdose mortality also varied by race/ethnicity and other demographic factors

(Figure 5). Non-Hispanic Black and African Americans had the largest decrease in overdose

death rates between 2023 and 2024 of any group assessed, falling 29.3%. Nevertheless, this

group had an overdose death rate in 2024 of 36.0 per 100,000, substantially higher than the

national average of 23.7. Non-Hispanic American Indian and Alaska Native individuals had the

highest overdose mortality rate of any group assessed in 2024, at 50.8, and experienced below-

average decreases between 2023 and 2024, of 20.1%. Non-Hispanic White individuals had

below-average overdose death rates in 2024 of 24.8 and saw declines similar to the national

average.

Relative decreases in overdose death rates were slightly higher among males than females, with

25.7% and 21.1% decreases, respectively. The largest percent decreases in overdose death rates

were seen among individuals aged 15-24 (35.7% decrease) and 25-34 years (31.9% decrease).

Older individuals generally had smaller decreases, and individuals age ≥75 experienced a small

increase (of 2.9%).

**Discussion**

The US is in the midst of a historic moment in the trajectory of the overdose crisis, as mortality

rates decreased steadily between mid-2023 through the end of 2024. Previous studies have

demonstrated that overdose deaths in the US could be described nearly perfectly with an

exponential growth curve.[6,13] Here we find that for the first time since the early 2000s, death

rates fell below this exponential growth pattern. Prior deviations from the exponential curve

have been documented, but these have generally included transient deviations above the curve,

followed by return to exponential growth.[13] Our findings suggest that the downward trends

observed in 2023-2024 represent the first sustained, high-magnitude departure below

exponential growth in the modern history of the US overdose crisis.

The permanence of this encouraging trend will depend on future shifts in the illicit drug market,

substance use behaviors, and policies. Despite progress, overdose death rates in the US remain

at about 400% of the magnitude seen at the turn of the century in the year 2000 and continue

to be far higher than those among other developed nations.[19] The nearly 80,000 lives lost to

overdose in 2024 remains a staggering quantity of preventable mortality.

Although the beginning of these downward trends was previously reported,[3] here we provide

newfound details documenting the continued trajectory, significance, and profundity of these

changes. We show that in 2024, for the first time, wave four of the crisis (defined by fentanyl in

combination with stimulants), is also decreasing in magnitude. We also highlight that not all

segments of the US overdose crisis are shrinking. Fatalities involving stimulants and xylazine

have grown and continue to represent important public health challenges. Importantly, other

novel substances, such as medetomidine, nitazenes, designer benzodiazepines, and carfentanil

have emerged in hotspots across the country.[10,20–23] Should one or more of these novel

synthetic substances proliferate widely and drive rising overdose risk, a return to exponential

growth could occur at a national level.

Our findings also suggest that stimulants and xylazine are each likely to continue to represent

growing challenges. We find that cocaine- and methamphetamine-involved deaths increased in

recent years and represent a growing share of all overdose fatalities. Other stimulant-related

health harms such as substance-induced psychosis, have also risen.[24] It is important to note that

the majority of stimulant-related burden of disease stems from slower epidemiological

processes compared to overdose, such as morbidity and accelerated mortality due to

cardiovascular, neurovascular, pulmonary, and psychiatric consequences.[25] As stimulants

continue to induce a growing share of addiction-related burden of disease, a focus on overdose

mortality as the defining indicator of the public health impact of substance use disorders may

be increasingly insufficient. Instead, more comprehensive measures such as disability adjusted

life years (DALYS)[25] that account for morbidity may more completely reflect the trajectory of the

US addiction crisis.

Recent decreases in overdoses have not occurred equally by geography, and some marked

reversals of prior trends were observed. After decades of being the least affected region,

overdose deaths are now the highest in the Western US. This may reflect the lagged course of

the overdose crisis in the West, with the region trailing behind the rest of the country in

decreases. Alternatively, it may reflect other unique dynamics in the Western region of the US,

including distinct illicit drug supply lines, a higher availability of illicitly manufactured fentanyl

(especially in pill form), and hotspots with increasing fentanyl use.[22,26,27]

After several years of rapidly widening inequalities in race/ethnicity, 2024 showed some small,

albeit encouraging, decreases in disparities in overdose mortality, with Black and African

Americans having the largest relative decrease between 2023 and 2024, falling by nearly one-

third in a single year. Nevertheless, the magnitude of inequalities remains quite large. In

particular, the mortality rate among American Indian and Alaska Natives remained double that

of the general population. Policies targeting community and system level factors associated with

inequitable health will be needed to address these persistent disparities.[12,28,29]

The decreases in overdose mortality in 2023-2024 in the US are likely multifactorial in nature,

reflecting several overlapping epidemiological and demographic phenomena.[3,30,31] Deaths have

now returned to pre-pandemic levels, as numerous social, economic, and epidemiological

consequences of the pandemic have also begun to recede.[14] The availability and use of the

opioid overdose antidote naloxone have been considerably scaled up in recent years, which is

likely playing an important role. Some evidence suggests that shifts in the illicit fentanyl supply

are also key to driving recent dynamics, with lower potency and variability of illicit opioids, and

the inclusion of high rates of fillers and adulterants leading to a lower overall opioid

potency.[30,32] The widespread shift from injecting to smoking opioids has also been associated

with decreased overdose rates.[33,34] There are also likely a reduced number of individuals that

are susceptible to overdose, given increased awareness of the risks of illicit fentanyl, and the

premature mortality of a large segment of previously susceptible individuals.[3,30] Further

research is needed to assess the relative contribution of each of these factors to the observed

decreases, and guide continued prevention.

Some of these observed trends may also simply reflect, at least in part, an overall 'regression to

the mean' as trends homogenize in the context of nearly universal decreases. Examining

demographic and geographic categories highlights that the states and demographic groups with

the highest mortality rates generally experienced the greatest decreases.

**Limitations**

Caution should be used in extrapolating from the gains achieved in 2024 to future decreases.

Due to inherent lags in overdose toxicology testing, the mortality records from 2024 are

provisional in nature and may change when final records are subsequently released.[35] However,

in previous years, differences between provisional and final trends have been relatively small

and have not changed the overall directionality of trends. Additionally, the race/ethnicity

categorizations used here have limitations, especially for among American Indian and Alaska

Native individuals, which may mask the magnitude of inequalities[36].

**Conclusions**

Recent decreases in overdose deaths are encouraging, relatively unprecedented, and represent

the first major deviation below the exponential growth curve since the start of the US overdose

crisis. However, policymakers, clinicians, and public health officials should be prepared for the

possibility that a return to exponential growth could occur, especially if novel synthetic drugs

once again dramatically change the risk environment of illicit drug use.

Despite recent progress, US overdose mortality remains a global outlier.[19] The country saw

about 80,000 deaths in 2024. If the US population had the same overdose death rate as

Western Europe, about 9,000 lives would have been lost.[25] Greater investments are needed to

sustainably reverse the course of this large-magnitude, preventable mortality crisis, via

evidence-based approaches such as medications for opioid use disorder, harm reduction, and

access to addiction-related treatment.

Some encouraging, yet very early, improvements in racial/ethnic inequalities in overdose

mortality have also been seen, after profoundly worsening during the COVID-19 pandemic.[12] Yet

disparities remain, even as the national trend in deaths now declines. More progress can be

made with tailored solutions to reduce overdose deaths among the most affected groups.[12]

**Funding**

JRF received funding from the National Institute on Drug Abuse (DA049644) and the National

Institute of Mental Health (MH101072). JP received support from the National Institute on Drug

Abuse of the National Institutes of Health (R01DA057289 and U01DA051126). CLS was

supported by National Institute on Drug Abuse (R01DA057630; K01DA05771**).** AB was

supported by National Institute on Drug Abuse (R33DA061260 and DP2DA049295). Funders

had no role in the design and conduct of the study; collection, management, analysis, and

interpretation of the data; preparation, review, or approval of the manuscript; and decision to

submit the manuscript for publication.

**Conflicts of Interest**

JP reported receiving personal fees from the Washington-Baltimore High Intensity Drug

Trafficking Areas program, Elsevier, Wiley, Rutgers University, Arizona State University, the

University of Southern California, Queensland University, the National Network of Public Health

Institutes, Alta Mira Recovery programs, and Dartmouth University, and nonfinancial support

from NIH/NIDA, the University of Florida, Rx Summit, the American College of

Neuropsychopharmacology, and the Reagan-Udall Foundation for the FDA during the conduct of

the study. DC reports personal fees from Celero Systems, and Motley-Rice LLC outside the

submitted work. All other authors declare no conflict of interest.

**Figure 1. Simplified Representation of the Four Waves of the US Overdose Crisis**
Based on the general approach from Friedman and Shover, the four waves of the US overdose crisis are shown in a simplified schema. Wave one is represented by prescription opioids (with fentanyl co-involvement deleted), wave 2 is shown by deaths involving heroin (without fentanyl). Wave 3 and 4 correspond to fentanyl-involved deaths without, and with, stimulants, respectively. Xylazine and stimulants without fentanyl are shown as examples of more recent drug trends that are not decreasing. Note that most xylazine-involved deaths also involve fentanyl. Data from 2024 are provisional and may slightly underestimate final numbers.

**Figure 2. Overdose Death Rates by Year and Substance Co-Involvement, 1980-2024**
A) National-level estimates of overdose deaths per 100,000 are shown by year from 1980 to 2024. Following the general approach established by Jalal et al., an exponential line of best fit is shown, estimated using data from 1980-2016 with a 95% uncertainty interval. The vertical dashed line shows the portion of the graph corresponding to part B, for which drug-specific data were available from 1999-2024. B) Drug overdose death rates per 100,000 are shown by specific substance involvement. Fentanyl-involved deaths are shown separately by stimulant co-involvement status. *Deaths for methamphetamine (meth), cocaine, commonly prescribed opioids (Rx Opioids) and heroin are shown removing deaths co-involved with fentanyl. Data from 2024 are provisional and may slightly underestimate final numbers.

**Figure 3. Monthly Overdose Mortality by Region, 2018-2024**
The death rate per 100,000 people is shown by month and US Census Region. Monthly data are annualized by multiplying by 12 to reflect the magnitude of annual mortality rates. Monthly data for the entire US are also shown in Black. Data from 2024 are provisional and may slightly underestimate final numbers.

**Figure 4. Overdose Deaths by Stimulant and Fentanyl Involvement**
The total number of annual overdose deaths each year is shown by categories of fentanyl and stimulant involvement. Data from 2024 are provisional and may slightly underestimate final numbers.

**Figure 5. Percent Change and Level of Overdose Deaths Between 2023-2024**
Top: percent change in overdose death rate is shown between 2023 and 2024 for several stratifying variables. A horizontal dashed line shows the national average decrease in overdose deaths for this period. Region and county refer to the geography of residence of each death, not occurrence location of the deceased. Data are shown from the 10 counties and 10 states with the highest total number of deaths in 2024. Bottom: the death rate per 100,000 in 2023 and 2024 is shown for the same stratifying variables. A horizontal dashed line shows the average overdose mortality rate in 2024. Data from 2024 are provisional and may slightly underestimate final numbers.

**Figure 6. State-Level Percent Change and Level in Overdose Deaths, 2024**
Top: the percent change in overdose deaths between 2023 and 2024 is shown for the continental US by state.  State refers to the geography of residence of each death, not occurrence location of the deceased. States are classified according to quartiles of decreases in percent change, or increasing status, for a total of 5 categories. Bottom: the death rate per 100,000 population is shown by state for 2024, with quintiles shown by color. Data from 2024 are provisional and may slightly underestimate final numbers.

# References

1. *U.S. Overdose Deaths Decrease in 2023, First Time Since 2018*. Centers for Disease Control and Prevention; 2024. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm

2. Ahmad F, Cisewski J, Rossen L, Sutton P. *Provisional Drug Overdose Death Counts. National Center for Health Statistics. 2025.*; 2020. https://dx.doi.org/10.15620/cdc/20250305008

3. Post LA, Ciccarone D, Unick GJ, et al. Decline in US Drug Overdose Deaths by Region, Substance, and Demographics. *JAMA Netw Open*. 2025;8(6):e2514997. doi:10.1001/jamanetworkopen.2025.14997

4. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. *Current Opinion in Psychiatry*. 2021;34(4):344-350. doi:10.1097/YCO.0000000000000717

5. Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021. *Addiction*. 2023;118(12):2477-2485. doi:10.1111/add.16318

6. Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. *Science*. 2018;361(6408):eaau1184. doi:10.1126/science.aau1184

7. Friedman J, Kim D, Schneberk T, et al. Assessment of Racial/Ethnic and Income Disparities in the Prescription of Opioids and Other Controlled Medications in California. *JAMA Internal Medicine*. 2019;179(4):469-476. doi:10.1001/jamainternmed.2018.6721

8. Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. *Int J Drug Policy*. 2019;71:183-188. doi:10.1016/j.drugpo.2019.01.010

9. Friedman JR. Assessing an ICD-10 Code Approach for Estimating Xylazine-Involved Overdose Deaths in the United States. *Drug and Alcohol Dependence*. Published online July 2025:112781. doi:10.1016/j.drugalcdep.2025.112781

10. Gupta Rahul, Holtgrave David R., Ashburn Michael A. Xylazine — Medical and Public Health Imperatives. *New England Journal of Medicine*. 2023;388(24):2209-2212. doi:10.1056/NEJMp2303120

11. Shover CL, Falasinnu TO, Dwyer CL, et al. Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance. *Drug Alcohol Depend*. 2020;216:108314. doi:10.1016/j.drugalcdep.2020.108314

12. Friedman JR, Nguemeni Tiako MJ, Hansen H. Understanding and Addressing Widening Racial Inequalities in Drug Overdose. *AJP*. 2024;181(5):381-390. doi:10.1176/appi.ajp.20230917

13. Jalal H, Burke DS. Exponential growth of drug overdose poisoning and opportunities for intervention. *Addiction*. 2022;117(5):1200-1202. doi:10.1111/add.15841

14. Friedman J, Akre S. COVID-19 and the Drug Overdose Crisis: Uncovering the Deadliest Months in the United States, January–July 2020. *Am J Public Health*. Published online April 15, 2021:e1-e8. doi:10.2105/AJPH.2021.306256

15. CDC WONDER. https://wonder.cdc.gov/

16. Compton WM, Einstein EB, Jones CM. Exponential increases in drug overdose: Implications for epidemiology and research. *International Journal of Drug Policy*. 2022;104:103676. doi:10.1016/j.drugpo.2022.103676

17. Han B, Cotto J, Etz K, Einstein EB, Compton WM, Volkow ND. Methamphetamine Overdose Deaths in the US by Sex and Race and Ethnicity. *JAMA Psychiatry*. Published online January 20, 2021. doi:10.1001/jamapsychiatry.2020.4321

18. O'Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J. Trends in and Characteristics of Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls — United States, 2019–2020. *MMWR Morb Mortal Wkly Rep*. 2021;70(50):1740-1746. doi:10.15585/mmwr.mm7050e3

19. Gumas E. *U.S. Overdose Deaths Remain Higher Than in Other Countries — Trend-Tracking and Harm-Reduction Policies Could Help*. Commonwealth Fund; 2025. https://www.commonwealthfund.org/blog/2025/us-overdose-deaths-remain-higher-other-countries-trend-tracking-and-harm-reduction?check_logged_in=1

20. Palamar JJ, Krotulski AJ. Medetomidine Infiltrates the US Illicit Opioid Market. *JAMA*. 2024;332(17):1425. doi:10.1001/jama.2024.15992

21. Samarasekera U. "Even worse than fentanyls": nitazenes in the USA. *The Lancet*. 2024;404(10469):2250-2251. doi:10.1016/S0140-6736(24)02663-1

22. Friedman J, Ciccarone D. The public health risks of counterfeit pills. *The Lancet Public Health*. 2025;10(1):e58-
e62. doi:10.1016/S2468-2667(24)00273-1
23. Ciccarone D. The Donovan Memorial Lecture: 'Fentanyl-Plus': A New Era of Fentanyl Polydrug Combinations in
The North American Overdose Crisis. *Journal of Medical Toxicology*. 2025;In Press.
24. Calcaterra SL, Yamkovoy K, Swathi PA, et al. U.S. trends in methamphetamine-involved psychiatric
hospitalizations in the United States, 2015-2019. *Drug Alcohol Depend*. 2024;262:111409.
doi:10.1016/j.drugalcdep.2024.111409
25. Naghavi M, Ong KL, Aali A, et al. Global burden of 288 causes of death and life expectancy decomposition in
204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global
Burden of Disease Study 2021. *The Lancet*. 2024;403(10440):2100-2132. doi:10.1016/S0140-6736(24)00367-2
26. Palamar JJ, Fitzgerald N, Carr TH, Cottler LB, Ciccarone D. National and regional trends in fentanyl seizures in
the United States, 2017–2023. *International Journal of Drug Policy*. Published online May 13, 2024:104417.
doi:10.1016/j.drugpo.2024.104417
27. Montero F, Bourgois P, Friedman J. Potency-Enhancing Synthetics in the Drug Overdose Epidemic: Xylazine
("Tranq"), Fentanyl, Methamphetamine, and the Displacement of Heroin in Philadelphia and Tijuana. *Journal*
*of Illicit Economies and Development*. 2022;4(2):204-222. doi:10.31389/jied.122
28. Gondré-Lewis MC, Abijo T, Gondré-Lewis TA. The Opioid Epidemic: a Crisis Disproportionately Impacting Black
Americans and Urban Communities. *J Racial and Ethnic Health Disparities*. 2023;10(4):2039-2053.
doi:10.1007/s40615-022-01384-6
29. Bauer C, Hassan GH, Bayly R, et al. Trends in Fatal Opioid-Related Overdose in American Indian and Alaska
Native Communities, 1999–2021. *American Journal of Preventive Medicine*. 2024;66(6):927-935.
doi:10.1016/j.amepre.2024.01.019
30. Dowell D, Nataraj N, Rikard M, Park J, Zhang K, Baldwin G. Why have overdose deaths decreased? Widespread
fentanyl saturation and decreased drug use among key drivers. *The Lancet Regional Health – Americas*.
doi:10.1016/j.lana.2025.101226
31. *CDC Reports Nearly 24% Decline in U.S. Drug Overdose Deaths*.; 2025.
https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-drug-overdose-deaths.html
32. Shover CL, Koncsol AJ, Godvin ME, et al. High variation in purity of consumer-level illicit fentanyl samples in Los
Angeles, September 2023–April 2025. *International Journal of Drug Policy*. 2025;145:104977.
doi:10.1016/j.drugpo.2025.104977
33. Eger WH, Abramovitz D, Bazzi AR, et al. Changes in injecting versus smoking heroin, fentanyl, and
methamphetamine among people who inject drugs in San Diego, California, 2020–2023. *Drug and Alcohol*
*Dependence*. 2024;259:111318. doi:10.1016/j.drugalcdep.2024.111318
34. Karandinos G, Unick J, Ciccarone D. Mortality risk among individuals who smoke opioids compared with those
who inject: A propensity score-matched cohort analysis of United States national treatment data. *Addiction*.
2025;120(5):1040-1045. doi:10.1111/add.16740
35. Spencer MR. Timeliness of Death Certificate Data for Mortality Surveillance and Provisional Estimates. *CDC*
*Vital Statistics Rapid Release*. Published online 2016:8.
36. Anderson RN, Copeland G, Hayes JM. Linkages to Improve Mortality Data for American Indians and Alaska
Natives: A New Model for Death Reporting? *Am J Public Health*. 2014;104(S3):S258-S262.
doi:10.2105/AJPH.2013.301647